TOTAL: $336.25M Company (Symbol)# Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised ($M)* Investors; Placement Agents; Details (Date)@ Abgenix Inc. (ABGX) Private placement of common stock 1.8S $75 Abgenix sold 1.8M shares of common stock to selected institutional and other accredited investors at $42 per share; Pacific Growth Equities served as placement agent (11/15) Avigen Inc. (AVGN) Private placement of common stock and warrants ND $40 Avigen sold an

I. COMMENCED TRADING IN NOVEMBER Company (Symbol) Date Filed Date Comm. Shares/Units (M) Price (M) Shares Out Lead, Other Underwriters# Gross ($M) Net ($M) INITIAL OFFERINGS Genomics One Corp.1 (Canada; MSE:GNX) 10/19 11/24 3U (US$0.85) C$1.25 (US$2.56) ND PGS C$3.75 (US$2.18) C$3.2 (US$XX) Oncolytics Biotech Inc.2 (Canada; ASE:ONC) 9/20 11/8 4S C$0.85 (US$0.58) ND CCC C$3.4 (US$2.3) C$3 (US$2.04) Symyx Technologies Inc.3 (SMMX) 9/21 11/17 5.5S $14 27.7

By Nancy Volkers Special to BioWorld Financial Watch While most of the country is thinking about Y2K, the biotech industry seems to be concentrating on a different acronym: IPO. Initial public offerings have been slow all year. Besides Genentech Inc.'s nearly $2 billion offering in July, the biotech sector has seen only three companies go public between June and October ­ raising $141 million ­ and only two others file to go public. Last year looked much the same, to a point. IPO

Company* (Symbol) Product Description Indication Status/Date** CANCER Inex Pharmaceuticals Corp. (Canada;TSE:IEX) INX-3280 Anticancer therapeutic that targets the c-myc gene, believed to be a factor in the uncontrolled cell growth characteristic of tumors Solid tumors and lymphoma Filed an investigatonal new drug (IND) application with the Therapeutics Product Programme of Health Canada for approval to begin Phase I trials of INX-3280 in combination with cisplatin (10/13) Scotia

Company (Symbol)* Product Description Indication Action/Date** CANCER Cell Pathways Inc. (CLPA) Aptosyn Exisulind; cyclic GMP phosphodiesterase inhibitor Familial adenomatous polyposis FDA accepted the company's new drug application (NDA) (10/25) Genta Inc. (GNTA) G-3139 Bcl-2 antisense compound designed to reduce the Bcl-2 protein level in cancer through an antisense mechanism that specifically targets the messenger-RNA produced by the bc-2 gene Malignant melanoma Received

Company* (Symbol) Product Description Indication Status (Date)** CANCER Calydon Inc.* CV787 Second-generation virus; a prostate-specific gene incorporated into an attenuated adenovirus Prostate cancer patients seeking alternatives to radiation or radical surgery Commenced Phase I/II trial (10/25) Cell Pathways Inc. (CLPA) Aptosyn (Exisulind) A selective apoptotic, anti-neoplastic compound that inhibits a cyclic GMP phosphodiesterase and selectively induces apoptosis in abnormally

By Randall Osborne Editor A contest for shares of the rheumatoid arthritis (RA) market is shaping up, as Amgen Inc. steps into the fray with Phase II data that the company plans to use in its application to the FDA for a biologics license to market Kineret. The drug is an interleukin-1 (IL-1) receptor antagonist. Others, such as Centocor Inc.'s Remicade (infliximab) and Immunex Corp.'s Enbrel (etanercept), work by blocking the activity of tumor necrosis factor (TNF), the second cytokine

Biotech Co.* (Symbol) Pharma Co. (Symbol/Country) Product Amount Terms/Details (Date)** Affymetrix Inc. (AFFX) Novartis Institute GeneChip Array technology for Functional Genomics (a unit of Novartis AG; Switzerland) ND The agreement provides for volume-based pricing for GeneChip array purchases and a broad technical collaboration between Novartis Institute and Affymetrix scientists to develop new applications for GeneChip arrays; the Scripps Research Institute and the Novartis

Biotech Co.* (Symbol) Pharma Co. (Symbol/Country) Type/Product Area Amount Terms/Details (Date)** I. MODIFIED AGREEMENTS Adolor Corp.* Roberts Pharmaceutical Corp. (AMEX:RPC) Adolor exercised its option, acquired 6/98, for an exclusive worldwide license to the compound ADL 8-2698 ND Adolor will expand the clinical testing program of ADL 8-2698; Adolor made an undisclosed milestone payment to Roberts in connection with the exercise of the options further details ND (10/99

By Randall Osborne Editor As the influenza virus begins its march across the nation, a pair of preventive treatments are jostling for market position, while a promising vaccine ­ Aviron's FluMist ­ is held back by problems with testing and manufacturing. Glaxo Wellcome Inc., a subsidiary of London-based Glaxo Wellcome plc, is sending its recently approved flu therapy, inhaled Relenza (zanamivir), into the world. Also approved last month was the pill Tamiflu (oseltamivir phosphate

Biotech Co.* (Symbol) Pharma Co. (Symbol/Country) Type/Product Area Amount (M) Terms/Details (Date) Alteon Inc. (ALTN) Taisho Pharmaceutical Co. Ltd.* (Japan) License agreement/Alteon's lead crosslink breaker, ALT-711 ND Taisho was granted an exclusive option through 12/99 to acquire a license to ALT-711 for Japan, South Korea, Taiwan and China; financial details ND (9/99) Amylin Pharmaceuticals Inc. (AMLN) Linco Research Inc.* License agreement/Proprietary antibodies developed by

By Randall Osborne Editor The much-touted promise of gene therapy lost credibility ­ and could lose financial backing ­ with disclosures by the National Institutes of Health (NIH) that six patients died during research at the New York Hospital-Cornell Medical Center and Tufts University. This news followed a fatality in a gene-therapy program at the University of Pennsylvania, which led the FDA to order Schering-Plough Corp. to halt two gene therapy studies that shared one key similarity

I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $184.4M Company Location Date@ Amt.* (M) Details Ambryx Inc. (1st Round) San Diego 10/25 $12.3 Ambryx completed a private placement of Series A preferred stock; placement agent was BayCity Capital; other participants included Domain Associates, Prospect Venture Partners, Kingsbury Capital, Rho Management Co., and a group of individual investors including the company's founders, Dr. Lubert Stryer and Paul A. Grayson Dendreon Corp

TOTAL: $218.96M Company (Symbol)# Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised ($M)* Investors; Placement Agents; Details (Date)@ Amylin Pharmaceuticals Inc. (AMLN) Private placement of common stock 3.7S $18.5 Amylin raised $18.5M in a private placement of 3.7M shares of common stock at $5 per share; investors included members of the company's board of directors and their affiliated funds (10/7) Aphton Corp. (APHT) Private placement of common stock 0.8S

I. COMMENCED TRADING IN OCTOBER Company (Symbol) Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Lead, Other Underwriters# Gross ($M) Net ($M) INITIAL OFFERINGS No initial public offerings commenced in October. FOLLOW-ON OFFERINGS Biovail Corp.1 (NYSE, TSE:BVF) ND 10/20 5S C$74.8 US$51 ND DLJ, ML, MSDW, BAS, PZC, DLJD, MLC, RBC, YS, CIBC, DS, HSBCS, NBFC, SMcL, TDS C$373.8 US$255 C$354.8 US$242E Connetics Corp.2 (CNCT) 8/24 10/1 4.8S $6 25.6 WDR

By Randall Osborne Editor Showing up as not much more than a blip on the quiet screen of initial public offering (IPO) radar was Tularik Inc.'s registration to seek about $70 million, and much of the action remained in private placements ­ such as the agreement by publicly held Transkaryotic Therapies Inc. (TKT) to issue 3.3 million shares of common stock that will provide the company with $132 million. The funding will be used to advance its products for Fabry disease and anemia. "It's a

By Debbie Strickland Special to BioWorld Financial Watch With multiple high-profile approvals in the last two years, monoclonal antibodies seem to be finally coming of age as a major means of generating large numbers of drug candidates for a variety of disease targets. The recent approvals include Rituxan (rituximab), developed by IDEC Pharmaceuticals Corp., of San Diego, and Genentech Inc., of South San Francisco, for certain forms of non-Hodgkin's lymphoma; Zenapax (daclizumab

Company* (Country, Symbol) Company# (Country, Symbol) Type/Product Area Terms/Details (Month) Acadia Pharmaceuticals* Allergan (NYSE:AGN) License and research collaboration agreement to discover, develop and commercialize compounds for glaucoma, based on Acadia's receptor subtype-selective muscarinic lead compounds Acadia will grant Allergan worldwide rights to products based on Acadia's novel lead compounds for treatment of ocular disease; Acadia will provide its expertise in medicinal

By Debbie Strickland Special To BioWorld Financial Watch The Human Genome Project will provide a major revenue stream this year for Genome Therapeutics Corp., which has landed two sequencing contracts worth a combined $28 million. Like much non-proprietary research, the sequencing contracts are not expected to be profitable in themselves, said Lynn Doucette-Stamm, director of genomics and the GTC Sequencing Center. Still, she noted, "It reduces our overall cost in sequencing. It brings